Toronto Dominion Bank’s Adverum Biotechnologies ADVM Stock Holding History

Toronto Dominion Bank’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	1291
2022 Q1	$0	Hold	1	–	–	﹤0.01%	1381
2021 Q4	$0	Buy	+1	New	+$20	﹤0.01%	1486

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Toronto Dominion Bank's ADVM Position: Q2 2022 in Review

Toronto Dominion Bank sold out of Adverum Biotechnologies (ADVM) in Q2 2022, closing a stake of 1 share.

Toronto Dominion Bank first reported a position in ADVM in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 77 funds tracked by Wall St. Rank hold ADVM as of Q2 2022.

Toronto Dominion Bank reported no remaining Adverum Biotechnologies position as of Q2 2022 after selling out during the quarter.
Toronto Dominion Bank sold 1 Adverum Biotechnologies share in Q2 2022.
Toronto Dominion Bank first reported a position in Adverum Biotechnologies in Q4 2021 and held it in 2 quarters.
Toronto Dominion Bank's Adverum Biotechnologies position peaked at $0 in Q1 2022.
77 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2022.

Based on Toronto Dominion Bank's 13F filing for Q2 2022, filed 11 Aug 2022.